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Expanding the Substantial Interactome of NEMO Using
Protein Microarrays
Beau J. Fenner, Michael Scannell, Jochen H. M. Prehn*
Centre for Human Proteomics and Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland
Abstract
Signal transduction by the NF-kappaB pathway is a key regulator of a host of cellular responses to extracellular and
intracellular messages. The NEMO adaptor protein lies at the top of this pathway and serves as a molecular conduit,
connecting signals transmitted from upstream sensors to the downstream NF-kappaB transcription factor and subsequent
gene activation. The position of NEMO within this pathway makes it an attractive target from which to search for new
proteins that link NF-kappaB signaling to additional pathways and upstream effectors. In this work, we have used protein
microarrays to identify novel NEMO interactors. A total of 112 protein interactors were identified, with the most statistically
significant hit being the canonical NEMO interactor IKKbeta, with IKKalpha also being identified. Of the novel interactors,
more than 30% were kinases, while at least 25% were involved in signal transduction. Binding of NEMO to several
interactors, including CALB1, CDK2, SAG, SENP2 and SYT1, was confirmed using GST pulldown assays and
coimmunoprecipitation, validating the initial screening approach. Overexpression of CALB1, CDK2 and SAG was found to
stimulate transcriptional activation by NF-kappaB, while SYT1 overexpression repressed TNFalpha-dependent NF-kappaB
transcriptional activation in human embryonic kidney cells. Corresponding with this finding, RNA silencing of CDK2, SAG
and SENP2 reduced NF-kappaB transcriptional activation, supporting a positive role for these proteins in the NF-kappaB
pathway. The identification of a host of new NEMO interactors opens up new research opportunities to improve
understanding of this essential cell signaling pathway.
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Introduction
Nuclear factor k-light chain enhancer of activated B cells (NF-
kB) is a global transcriptional regulator found in most animal cells
and is involved in responses to a wide variety of stimuli including
cytokines such as TNFa, pathogens, free radicals, hypoxia, UV
irradiation and other stresses [1,2,3,4]. NEMO, the NF-kB
essential modulator, was originally described as being required
for activation of the NF-kB pathway in response to such stresses
[5]. Subsequent work revealed that the 48 kDa NEMO protein
serves as an adaptor that links stimulation of upstream signaling
components such as the membrane-bound TNFa and interleukin-
1 receptors to the activation of IkB kinase proteins, IKKa and
IKKb [6,7]. Once activated, the IKK proteins phosphorylate IkB,
targeting it for proteosomal degradation and liberating the NF-kB
transcription factor. Free NF-kB then enters the nucleus and
activates transcription of its target genes.
In the case of the TNFa receptor, cytoplasmic NEMO is
recruited to the stimulated TNFa receptor complex by binding to
K63-linked polyubiquitin chains that are conjugated to RIP1 upon
receptor activation [8,9,10]. Binding to the polyubiquitin chains is
mediated by the NEMO ubiquitin binding domain [11; see
Figure 1], which binds multiple forms of polyubiquitin but prefers
K63- over K48-linked polyubiquitin [12].
While the specific function of NEMO in relation to TNFa
receptor stimulation is its most well characterized role to date, a
growing body of work points to a far more variable role. In
response to genotoxic agents that induce genomic DNA strand
breaks, NEMO acts independently of IKKa and IKKb by
entering the nucleus and associating with ATM [13], a process
that depends on NEMO SUMOylation [14]. ATM promotes
NEMO phosphorylation and, by mechanisms that remain
unclear, NEMO is deSUMOylated, ubiquitinated and leaves
the nucleus to activate the canonical IKK-dependent NF-kB
pathway [13,15]. Thus, at the very least, NEMO is predicted to
have a substantial interactome of both nuclear and cytoplasmic
proteins. Indeed, NEMO interactors identified to date include
proteins involved in apoptosis induction, heat shock response,
neuronal function and other cytokine signaling pathways
[16,17].
In the current work, we have used functional proteomics to
identify and characterize novel NEMO interactors. Using human
protein microarrays, we identified 112 NEMO binding proteins,
including a large number of signaling kinases and proteins related
to development and the cell cycle. Validation of a subset of the
interactors indicated that the screen did indeed yield authentic
NEMO binders, several of which were able to influence the
activity of the NF-kB signaling pathway.
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Results
Using Protein Arrays to Identify NEMO Interacting
Proteins
Identification of NEMO binding proteins was initially per-
formed by screening E. coli colony macroarrays containing more
than 30,000 recombinant human proteins (8,300 non-redundant
proteins) with full-length recombinant GST-NEMO. We previ-
ously used these macroarrays in our laboratory to identify
polyubiquitin binding proteins [12]. A screen of the macroarrays
that used GST-NEMO as a probe consistently revealed binding to
polyubiquitin and TANK (data not shown), both of which are
known NEMO interaction partners [8,18]. The canonical NEMO
interactor IKKb was present on the macroarray but no interaction
was detected with the NEMO probe. Previous work has indicated
that IKKb can indeed be expressed as a soluble protein in E. coli
[19], though we were consistently unable to show binding between
NEMO and this or any other protein on the macroarray other
than polyubiquitin and TANK.
To overcome the apparent limitations of the E. coli colony
macroarrays, we opted to use a human protein microarray
(Protoarray, Invitrogen) consisting of approximately 8,400 unique
human proteins expressed as GST or His6 fusions in an insect cell/
baculovirus expression system, with proteins being individually
purified and spotted onto nitrocellulose-coated glass slides.
Following purification and biotinylation of tag-free human NEMO
(Figure 1B) we applied the protein to the slides and detected bound
protein using streptavidin/Alexa Fluor-647. Biotinylated GST was
applied to a separate microarray as a negative control. Analysis of
the scanned NEMO array indicated that the biotin controls were
successful, with numerous positive hits being obtained (Figure 1C
and 1D).
Recombinant NEMO Has a Substantial Interactome In
Vitro
Statistically significant interactors were identified by measuring
the mean spot intensity for the microarray sectors and using a Z-
score of three (P= 0.002) as a cutoff value (Figure 1D).
Surprisingly, the GST control protein also bound a substantial
number of proteins on the array (data not shown), which were
considered as nonspecific interactors and where eliminated from
the NEMO interactor list where overlap occurred. This subtrac-
tion reduced the number of significant interactors from 200 to 112,
with a mean Z-score of 4.3361.36 (P,0.001), shown in Table 1
and Figure 1D. Among the final list, the majority of putative
NEMO interactors appeared to be completely novel, as only five
proteins, namely CALM2, IKKa, IKKb, MCM7 and TBK1 have
previously been shown to interact directly with NEMO [17].
Neither UbC nor TANK was present on the microarrays so it was
not possible to compare these results with those mentioned above
for the E. coli colony macroarrays.
An ontological analysis of the putative interactors revealed that
protein kinases were dramatically overrepresented in the dataset,
comprising at least 30% of all identified interactors compared to
the protein microarray used which only had 5% kinases
(Figure 2A). That said, of all kinases present on the array, the
kinases observed to significantly bind NEMO represented only 8%
of the total number of arrayed kinases, suggesting that the
interactions did not rely simply on a generic kinase motif.
Importantly, the identified NEMO-interacting kinases included
the canonical NEMO binding partners IKKa and IKKb
(Figure 1C, Table 1), with IKKb having the highest apparent
affinity for NEMO of all identified protein interactors. Given the
canonical role of IKKb as part of the IKK complex, this finding
was considered a strong validation of the specificity and usefulness
Figure 1. Probing of the human protein microarray with biotinylated recombinant NEMO. (A) Domain structure of the human NEMO
protein, showing the two coiled coil domains (CC1 and CC2), the NEMO ubiquitin binding domain (NUB), leucine zipper (LZ) and zinc finger (ZF). (B)
Immunoblot detection of biotinylated NEMO following purification of GST-NEMO, cleavage of the GST tag and biotinylation. Biotinylated NEMO was
detected with streptavidin-alkaline phosphatase conjugate. (C) Example hits obtained from the array, compared to the same spot positions on
negative control array. (D) Frequency histogram for the NEMO-probed protein microarray showing the range of Z-scores obtained. Protein interactors
with a Z-score greater than three (Z.3; P,0.002) were deemed significant. Scores obtained for the canonical NEMO interactors IKKalpha (Z= 6.52)
and IKKbeta (Z = 8.41) are shown for reference. Scores were calculated using Invitrogen Protoarray Prospector version 5.1 software. See Table 1 for
gene descriptions.
doi:10.1371/journal.pone.0008799.g001
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Table 1. Candidate NEMO interactors identified by protein microarray screening with full-length NEMO protein.
Gene Gene Product NCBI Accession Z-Score
Calcium binding
CETN3 Centrin EF-hand protein 3 BC005383 6.10
SYT1 Synaptotagmin I NM_005639 5.95
CPNE2 Copine II NM_152727 5.86
HPCAL1 Hippocalcin-like 1 NM_002149 4.20
MYL5 Myosin light chain 5, regulatory NM_002477 3.83
CALB1 Calbindin D28K NM_004929 3.61
TTYH2 Tweety homolog 2 BC004233 3.42
TPT1 Tumor protein, translationally-controlled 1 BC022436 3.40
DNA binding
H1F0 H1 histone family, member 0 BC029046 4.40
MCM7b MCM7 minichromosome maintenance deficient 7 BC009398 3.38
CNOT7 CCR4-NOT transcription complex, subunit 7 BC060852 3.21
GTPase
CENTA2 Centaurin, alpha 2 BC033758 4.06
TBC1D7 TBC1 domain family, member 7 NM_016495 3.13
GNGT1 G protein, c-transducing activity polypeptide 1 NM_021955 3.04
SEPT9 Septin 9 BC054004 3.03
Kinase
IKBKBb Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta NM_001556 8.41
PRKCB1 Protein kinase C type beta I X06318 8.33
TBK1b Tank binding kinase 1 NM_013254 7.37
PRKCB2 Protein kinase C type beta II X07109 6.83
IKBKAb Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase alpha NM_001278 6.52
LCK Leukocyte-specific protein tyrosine kinase M36881 5.97
CDK2 Cyclin-dependent kinase 2 NM_001798 5.34
FLT3 FMS-related tyrosine kinase 3 NM_004119 4.36
SRC2 Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog NM_005248 4.32
FLT3 D835Y FMS-related tyrosine kinase 3 (D835Y mutant) NM_004119 4.24
STK25 Serine/threonine kinase 25 NM_006374 4.21
PIM2 Pediatric index of mortality 2 NM_006875 4.13
EPHA4 Ephrin receptor A4 NM_004438 4.10
TEK TEK tyrosine kinase NM_000459 4.09
JAK2 Janus kinase 2 NM_004972 3.96
TEC Tyrosine kinase expressed in hepatocellular carcinoma NM_003215 3.92
FLT4 FMS-related tyrosine kinase 4 NM_182925 3.89
RPS6KB2 Ribosomal S6 kinase NM_003952 3.86
GRK4 G protein-coupled receptor kinase 4 NM_182982 3.84
PRKCN Protein kinase D3 NM_005813 3.66
MAP3K2 Mitogen-activated protein kinase kinase kinase 2 NM_006609 3.66
AKT1 v-akt murine thymoma viral oncogene homolog 1 BC000479 3.65
SGK1 Serum/glucocorticoid regulated kinase 1 NM_005627 3.62
ITK IL2-inducible T-cell kinase NM_005546 3.54
TYRO3 TYRO3 protein tyrosine kinase NM_006293 3.49
MERTK c-Mer proto-oncogene tyrosine kinase NM_006343 3.43
ALK Anaplastic lymphoma receptor tyrosine kinase NM_004304 3.42
JAK3 Janus kinase 3 NM_000215 3.36
RET RET proto-oncogene NM_020975 3.26
ROR2 Receptor tyrosine kinase-like orphan receptor 2 NM_004560 3.21
SRPK1 SFRS protein kinase 1 NM_003137 3.11
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Gene Gene Product NCBI Accession Z-Score
PCK1 Phosphoenolpyruvate carboxykinase 1 NM_002591 3.08
ROS1 c-Ros oncogene 1 NM_002944 3.08
DAPK1 Death-associated protein kinase 1 NM_004938 3.01
Protein binding
CUEDC1 CUE domain containing 1 NM_017949 7.38
RNF7 Ring finger protein 7 (sensitive to apoptosis gene, SAG) NM_014245 6.08
RBCK1 RanBP-type and C3HC4-type zinc finger containing 1 BC015219 5.25
PSMA3 Proteasome (prosome, macropain) subunit, alpha type, 3 NM_002788 5.19
WDR5 WD repeat domain 5, transcript variant 1 NM_017588 4.85
LZIC Leucine zipper and CTNNBIP1 domain containing NM_032368 4.41
ARL6IP4 ADP-ribosylation-like factor 6 interacting protein 4 NM_016638 4.25
PDCL Phosducin-like BC017227 4.04
PFDN5 Prefoldin 5, transcript variant 1 NM_002624 3.78
LPXN Leupaxin NM_004811 3.67
C9ORF32 Chromosome 9 open reading frame 32 BC001396 3.63
GADD45G Growth arrest and DNA-damage-inducible, gamma NM_006705 3.63
LUC7L2 LUC7-like 2 BC042625 3.62
GADD45GIP1 Growth arrest and DNA-damage-inducible, gamma interacting protein 1 BC013039 3.35
PHF7 PHD finger protein 7 NM_016483 3.27
SCLT1 Sodium channel and clathrin linker 1 BC064428 3.23
NAP1L5 Nucleosome assembly protein 1-like 5 NM_153757 3.20
TRIM41 Tripartite motif-containing 41 BC009762 3.20
APRT Adenine phosphoribosyltransferase NM_000485 3.19
KRT8 Keratin 8 BC008200 3.11
C19ORF57 Chromosome 19 open reading frame 57 BC012945 3.03
NECAB3 N-terminal EF-hand calcium binding protein 3 BC047673 3.03
MCM10 Minichromosome maintenance complex component 10 BC009108 3.01
RPAP3 RNA polymerase II associated protein 3 BC056415 3.00
RNA binding
RBM34 RNA binding motif protein 34 NM_015014 5.64
NOLA2 Nucleolar protein family A, member 2 NM_017838 5.41
EIF1AX Eukaryotic translation initiation factor 1A, X-linked NM_001412 4.30
DDX19B DEAD box polypeptide 19B, transcript variant 1 NM_007242 4.18
RBM8A RNA binding motif protein 8A NM_005105 3.92
ARL6IP4 ADP-ribosylation-like factor 6 interacting protein 4 BC015569 3.48
RPS12 Ribosomal protein S12 NM_001016 3.36
RPL41 Ribosomal protein L41 NM_021104 3.33
SIP1 Survival of motor neuron protein interacting protein 1, transcript variant alpha NM_003616 3.31
Transcription factor
MLLT6 Myeloid/lymphoid or mixed-lineage leukemia; translocated to, 6 BC064612 7.68
TCEANC TFS2-M domain-containing protein 1 NM_152634 7.28
TCP10L t-complex 10 (mouse)-like NM_144659 6.82
TCP11L1 t-complex 11 (mouse)-like 1 NM_018393 5.68
LMCD1 LIM and cysteine-rich domains 1 NM_014583 4.63
NRBF2 Nuclear receptor binding factor 2 BC011707 4.08
Other/unknown
FAM128A Family with sequence similarity 128, member A BC018206 7.32
TSLP Thymic stromal lymphopoietin, transcript variant 2 NM_138551 6.61
DNAJC8 DnaJ (Hsp40) homolog, subfamily C, member 8 NM_014280 5.84
FRMD8 FERM domain containing 8 BC051695 5.71
Table 1. Cont.
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of the screen. Other kinases with a high apparent affinity for
NEMO included PKCb1, PKCb2, LCK, CDK2, FLT3 and
another known NEMO binding partner, TBK1 (Table 1).
Further ontological analysis revealed that signal transduction
proteins formed the largest biological process category, with 25%
of the interactome, while 11% and 13% of interactors are involved
in cell cycle and development, respectively (Figure 2B). Despite the
well-characterized role of the NF-kB pathway in regulating cell
survival, only 9% of interactors are involved in apoptosis and cell
death-related processes, while 2% are related to stress responses.
As expected, the majority of identified NEMO interactors localize
to the cytoplasm and/or nuclear compartments (Figure 2C),
consistent with the known subcellular distribution of NEMO.
NEMO also interacted with the E3 ubiquitin ligases SAG and
RBCK1, which were previously reported to promote ubiquitina-
tion of NF-kB signaling components IkBa and TAB2/3,
respectively [20,21]. GST-NEMO also interacted with SYT1, a
major neuronal synaptic calcium sensor [22]. NEMO was
previously shown to interact with an extended variant of this
protein, termed E-SYT1 [17].
NEMO Binds to Putative Interactors Expressed in
Mammalian Cells
Based on our analysis of the list of putative NEMO interactors,
we selected five proteins of particular interest to validate the
microarray screen using GST pulldown and coimmunoprecipita-
tion assays. Proteins were chosen based on their previously
described roles related to NF-kB signaling. Calbindin D28K
(CALB1) is 28 kDa neuronal calcium binding protein that is
transcriptionally regulated by NF-kB following stimulation by
neurotrophic growth factor [23]. Cyclin-dependent protein kinase
2 (CDK2) associates with NF-kB during the G1/S phase transition
of the cell cycle [24], while sensitive to apoptosis gene 1 (SAG) is
an E3 ubiquitin ligase that appears to target IkBa for degradation
during the G1/S phase transition and in carcinogenesis [20,25].
The SUMO1-specific peptidase 2 (SENP2) was chosen due to the
role of SUMOylation in regulating the cellular localization of
NEMO [14,26]. Finally, synaptotagmin 1 (SYT1) was chosen due
to a previous finding indicating that NEMO can bind to an
extended SYT1 variant, E-SYT1 [17] and to the essential role of
synaptotagmin 1 in synaptic Ca2+ release [27,28,29].
Thus, HEK-293T cells were transfected with plasmids express-
ing CALB1, CDK2, SAG, SENP2 or SYT1. Additionally, an
IKKb expression vector was transfected as a positive control.
Using GST or GST-NEMO as bait proteins (Figure 3A), we found
that each of the five interactors was able to specifically bind GST-
NEMO, while little or no binding was observed with the GST
control (Figure 3B). These data suggested that the observed array
binding between NEMO and the interactors was indeed specific.
We next determined whether NEMO, when coexpressed with
each of the five interactors, was able to form a complex in vivo
using coimmunoprecipitation assays. Again, HEK-293T cells were
transfected with expression vectors for NEMO and the five
interactors, with IKKb or the parent vector serving as positive and
negative controls, respectively. In mammalian cells the parent
vector, pcDNA4-HisMaxA, expresses a 5.6 kDa irrelevant protein
in place of NEMO. As expected, IKKb immunoprecipitated only
in the presence of NEMO (Figure 3C). Similarly, each of the five
novel NEMO interactors also exhibited NEMO-specific immuno-
precipitation (Figure 3D–H), indicating that these proteins are can
form a complex with NEMO in vivo. In the case of SAG,
coimmunoprecipitation was observed in the presence of 0.1% NP-
Gene Gene Product NCBI Accession Z-Score
C19ORF12 Chromosome 19 open reading frame 12 NM_031448 5.51
TCP11 t-complex 11 (mouse) NM_018679 5.29
HBZ Hemoglobin, zeta NM_005332 4.59
FLJ11184 Hypothetical protein FLJ11184 BC011842 4.39
VAMP3 Vesicle-associated membrane protein 3 (cellubrevin) NM_004781 4.07
KIR3DX1 Killer cell immunoglobulin-like receptor, three domains, X1 BC033195 4.02
ARGLU1 Arginine and glutamate rich 1 BC050434 3.99
GYG2 Glycogenin 2 BC023152 3.91
PNMAL1 PNMA-like 1 BC051688 3.91
LGALS2 Lectin, galactoside-binding, soluble, 2 (galectin 2) NM_006498 3.72
ODAM Odontogenic, ameloblast associated NM_017855 3.54
AMMECR1L AMME chromosomal region gene 1-like NM_031445 3.53
PLEKHJ1 Pleckstrin homology domain containing, family J member 1 NM_018049 3.42
AVPI1 Arginine vasopressin-induced 1 NM_021732 3.33
SENP2 SUMO specific peptidase 2 NM_021627 3.32
ACBD6 Acyl-Coenzyme A binding domain containing 6 NM_032360 3.14
KIAA1598 Shootin-1 NM_001127211 3.05
NRARP NOTCH-regulated ankyrin repeat protein NM_001004354 3.04
ARPP-19 Cyclic AMP phosphoprotein, 19 kDa NM_006628 3.01
aThe Z-score indicates the how far the average spot intensity for a particular putative interactor fell from the mean of the relevant protein microarray sector spot
intensities, measured in standard deviations. A Z-score of greater than four standard deviations (P = 0.002) was deemed significant.
bThese proteins are known to interact directly with NEMO, based on the results of tandem affinity purification experiments [17].
doi:10.1371/journal.pone.0008799.t001
Table 1. Cont.
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40 detergent, but not with 0.5% NP-40, while the remaining four
proteins coimmunoprecipitated in the presence of 0.5% NP-40.
Finally, we used a two-hybrid system to validate the interactions
between NEMO and the five interactors. A control experiment
using two-hybrid luciferase vectors expressing NEMO and IkBa, a
known NEMO interactor [17], showed a clear two-hybrid
interaction between these two proteins when compared with the
corresponding negative control (Figure 3I). Similarly, significant
interactions were observed for each of the remaining NEMO
interactors compared to their negative controls, with CDK2
appearing to have the highest affinity for NEMO on the basis of
luciferase activity. A comparison between results obtained using
the two-hybrid method and Z scores obtained from the original
array screen did not reveal any obvious trend towards a high Z
score and a strong two-hybrid signal, suggesting that array-based
interactions do not correlate well to results obtained in a cellular
environment.
NEMO Interactors Influence NF-kB Transcriptional
Activation
To gain an understanding of how the identified interactors
might contribute to the NF-kB pathway, we cotransfected HEK-
293T cells with a secreted alkaline phosphatase (SEAP) NF-kB
transcriptional reporter plasmid and expression plasmids for the
five interactors. SEAP activity was then determined for cotrans-
fected cells in the presence or absence of TNFa, a potent
stimulator of NF-kB-dependent transcription. In the absence of
TNFa we found that CALB1, CDK2 and SAG all significantly
induced reporter activity (Figure 4A). After TNFa was added, we
again found that CALB1 and CDK2 overexpression increased
expression of the reporter above normal levels, while SYT1
substantially reduced induction of the reporter (Figure 4B). We did
not observe any significant influence of SENP2 overexpression on
reporter activity under these experimental conditions.
We next determined if transient siRNA-mediated mRNA
knockdown of the interactors led to any change in reporter
activity. For these experiments we chose to look at only CDK2,
SAG and SENP2 as these were expressed at readily detectable
levels in HEK-293T cells (data not shown), making mRNA
knockdown feasible. Cotransfection of the reporter plasmid with
control or specific siRNAs against these three putative NEMO
interactors led to a highly effective siRNA knockdown of more
than 80% by specific siRNAs compared to control siRNAs, based
on the results of RT-qPCR using gene-specific primers (Figure 4D).
Assays of reporter gene activity following gene knockdown yielded
modest but significant reductions of NF-kB transcriptional
activation for all three knockdowns when cells were treated with
TNFa, though no significant change was observed between
control and specific siRNA treatments in the absence of this
stimulator. Thus, at endogenous levels, CDK2, SAG and SENP2
can be considered as positive effectors of the TNFa-dependent
NF-kB pathway.
Discussion
Signal transduction by the NF-kB pathway is typically
considered as a ‘‘first response’’ mechanism as target gene
activation by the NF-kB transcription factor occurs rapidly after
stimulation by a wide variety of cellular stimuli. The position of
NEMO within this pathway would therefore necessitate its ability
to communicate with a large diversity of effectors to respond to
these different stimuli. In this study, we have uncovered an
exceptionally large number of NEMO interactors, most of which
are novel and not previously known to communicate with the
canonical NF-kB pathway.
While it is clear that many of the NEMO interactors identified
here, including IKKa and IKKb, are physiologically relevant, we
concede that a certain number of the array proteins may not
interact with NEMO in vivo. This could be due an inaccessible
subcellular localization, inappropriate temporal expression pat-
terns between NEMO and the interactors, or an overabundance of
NEMO and the interactors used during array screening [30].
Surprisingly, we also noted that several of the false positive hits
obtained on both the control and NEMO arrays have been
reported elsewhere to specifically bind other protein baits
[31,32,33]. While the interactions reported in those works may
well be authentic, the recurrence of a number of protein hits
during ProtoArray screens with other protein baits in our
laboratory suggests that certain arrayed proteins become artifi-
cially promiscuous when arrayed.
Among the novel NEMO interactors identified, calbindin
D28K and synaptotagmin 1 have well characterized neuronal
functions. Calbindin D28K is commonly described as a neuronal
calcium buffer that prevents the accumulation of toxic levels of
calcium via four calcium binding domains [34,35]. In addition to
this buffering role, however, calbindin D28K also appears to
function as a calcium sensor by interacting with downstream
effector proteins [34]. Neuronal calcium-sensing roles are also
played by three other novel NEMO interactors identified here and
elsewhere, namely calmodulin [17], hippocalcin-like 1 and
synaptotagmin 1. Our observation that calbindin D28K overex-
pression increased NF-kB activity points to calbindin D28K acting
Figure 2. Cytoplasmic and nuclear signaling kinases dominate
the NEMO interactome. Gene ontologies were determined for each
of the NEMO interactors and the results for each of the three standard
ontological categories plotted as percentages. Genes belonging to
more than one category were assigned to the category for which the
gene has been best characterized.
doi:10.1371/journal.pone.0008799.g002
Finding Novel NEMO Interactors
PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8799
as an inducer of the NF-kB pathway. This is in line with recent
findings indicating that the nuclear export NEMO and its
subsequent association with the IKK proteins is inducible by
calcium [36]. We also found that overexpression of synaptotagmin
1 markedly diminished TNFa-dependent NF-kB activity, which
would otherwise suggest that this protein is a repressor of the NF-
kB pathway. We remain skeptical of this idea, however, because
when synaptotagmin 1 is overexpressed in HEK-293 cells it
localizes almost homogeneously throughout the cell membrane
[37 and data not shown]. This may have had the unintended effect
of disrupting the activity or structure of the TNF receptor and thus
prevented proper activation of the NF-kB pathway upon TNFa
addition. It also remains to be seen how synaptotagmin 1 impacts
upon NF-kB activity in neurons and also whether or not NEMO is
indeed able to localize to the neuronal synapse where synapto-
tagmin 1 is normally present.
Another of the NEMO interactors, SAG, has been character-
ized as a cellular antioxidant whose overexpression markedly
reduces cell death following stroke or treatment with apoptosis
inducers [38,39]. The E3 ligase activity of SAG is known to
promote ubiquitination and subsequent degradation of IkBa,
resulting in activation of the NF-kB pathway [25]. It remains
unclear how the SAG-NEMO interaction impacts upon this
activity, though recent data from our lab suggests that overex-
pression of SAG can also promote ubiquitination of NEMO (B.
Fenner, unpublished results). Recent work has also revealed that
SAG is transcriptionally induced under hypoxia by HIF1a [40].
We are currently investigating the impact of SAG on hypoxia-
dependent induction of NF-kB.
Cyclin-dependent protein kinase 2, another of the novel NEMO
interactors identified here, associates with NF-kB during the G1/S
cell cycle transition [24]. We found that CDK2 is required for
maximal NF-kB activation in response to TNFa stimulation,
though we do not yet know whether this effect is mediated by
NEMO, NF-kB or another unidentified intermediate.
SUMOylation of NEMO retains the protein inside the nucleus,
and in response to certain cellular stresses NEMO is deSUMOy-
lated, exits the nucleus and promotes activation of the NF-kB
pathway [13,26,41,42,43]. It was therefore of special interest that
we identified SENP2, a nuclear-envelope-associated SUMO
Figure 3. Putative interactors bind to NEMO in GST pulldown, coimmunoprecipitation and mammalian two-hybrid assays. (A)
Immunoblot analysis of GST and GST-NEMO proteins used as control and bait for the pulldown assay. Proteins were detected using anti-GST/HRP
conjugate following SDS-PAGE and membrane transfer. (B) Results of GST pulldown assays showing binding of NEMO to putative interactors
identified by protein array screening. Each of the interactors and IKKbeta, a known NEMO binder, were overexpressed in transiently transfected HEK-
293T cells and the resulting lysates applied to immobilized GST or GST-NEMO. Following incubation and washing, the samples were resolved by SDS-
PAGE and the proteins detected using appropriate antibodies. Input lanes were loaded with 5–10% of HEK-293T lysates to confirm protein
expression. The size of relevant protein markers is shown beside the blot image. (C–H) Coimmunoprecipitation assays between NEMO and putative
binders in HEK-293T cells. Plasmids encoding Xpress-tagged NEMO or the empty parent vector and tagged putative binders were used to transfect
HEK-293T cells and the resulting cell lysates used for coimmunoprecipitation assays. For each putative binder, immunoblots are shown for detection
of the binder using a tag- or protein-specific antibody, and for detection of Xpress-tagged NEMO. For IKKbeta and each of the five putative
interactors, substantial coimmunoprecipitation occurred only in the presence immunoprecipitated NEMO. Input lanes contained 5–10% of the
precleared input volume used prior to addition of anti-Xpress antibody. Binding and washing steps were performed in the presence of 0.5% NP-40 for
all proteins except SAG, where 0.1% NP-40 was used. (I) NEMO interacts with CALB1, CDK2, SAG, SENP2 and SYT1 in a mammalian two-hybrid system.
Empty two-hybrid vectors were cotransfected as a negative control. The MyoD/Id and NEMO/IkappaBalpha protein pairs were used as positive
controls, while putative interaction partners cotransfected with empty complementing vector were used as negative controls. For each pair tested, a
significant increase (n = 6; two-tailed T test; P#0.05) in luciferase activity was obtained in partner/NEMO experiments compared to partner/vector
experiments (indicated by asterisks).
doi:10.1371/journal.pone.0008799.g003
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protease [44], as a NEMO interactor. Previous work indicates that
NEMO can be deSUMOylated by SENP1 [14], another nuclear
SUMO protease closely related to SENP2, and the activity of this
protein may explain why we observed such a modest effect on NF-
kB activity following efficient siRNA knockdown of SENP2. What
is more intriguing though is why SENP2 associated with NEMO
in what would presumably be the absence of SUMOylation during
the microarray screen. Current models of deSUMOylation by
SENPs do not suggest SUMO-independent recognition of a
SUMOylated protein by SENPs [45,46]. It may therefore be of
substantial interest to the field whether SENP2 can indeed
deSUMOylate NEMO in vivo and how this reaction proceeds in
relation to the SUMOylation status of NEMO.
We have identified several new NEMO protein interactors, and
have putatively identified over a hundred novel interactors using
protein microarrays. We expect that many researchers will be able
to use this list to gain new insight into how the NF-kB pathway
communicates with other signaling pathways. Future work from
our laboratory will focus on more detailed analyses of several of
the interactors and how they communicate with NEMO and the
NF-kB signaling pathways.
Materials and Methods
Preparation of Recombinant NEMO Probe
Human NEMO was expressed as a soluble GST fusion from the
pGEX-4T vector [10] in E. coli BL21(DE3) and purified using
glutathione sepharose (GE Life Sciences) as described previously
[10]. For screening of colony macroarrays, the GST-NEMO
fusion was used with the GST tag. For screening of protein
microarrays, the GST tag was removed following the final GSH-
sepharose washing step by adding thrombin (GE Life Sciences) as
suggested by the manufacturer, following by size exclusion
filtration using a 50 kDa cut-off Microcon filter (Millipore).
Approximately 15 mg of NEMO was then biotinylated using an
in vitro biotinylation kit as suggested by the manufacturer
Figure 4. NEMO interactors influence the transcriptional activation activity NF-kappaB. (A) Each of the five NEMO interactors was
overexpressed in untreated HEK-293T cells and their effect on NF-kappaB transcriptional activation measured by a reporter assay. CALB1, CDK2 and
SAG significantly increased reporter activity, indicated by asterisks (n = 4; two-tailed T test; P#0.05), while other genes had no effect compared to the
control vector transfection. Reporter activity is given in relative light units (RLU). (B) CALB1 and CDK2 overexpressed increases NF-kappaB activity in
TNFalpha treated cells, while SYT1 overexpression significantly represses activity (n = 4; two-tailed T test; P#0.05). (C) Confirmation of protein
expression following transfection of HEK-293T cells by immunoblot detection of native or epitope-tagged NEMO interactors. Little or no protein
expression was detected in the control vector transfected cells. (D) Knockdown of CDK2, SAG and SENP2 in HEK-293T cells mediated by siRNA
transfection. RNA levels at the time of NF-kappaB assays were measured by RT-qPCR and are displayed as percentage mRNA remaining after
knockdown compared to the amounts present in control siRNA-treated cells. Significant knockdown was seen for both of the genes, as indicated by
the asterisks (n = 3; two-tailed T test; P#0.05). (E) mRNA knockdown of CDK2, SAG and SENP2 reduces NF-kappaB transcriptional activation in
TNFalpha stimulated HEK-293T cells, but does not impact upon basal NF-kappaB activity in untreated cells (n = 4; two-tailed T test; P#0.05).
doi:10.1371/journal.pone.0008799.g004
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(Invitrogen) with a biotin:NEMO molar ratio of 9:1. Biotinylated
recombinant NEMO was stored at 280uC.
Protein Array Screening
ImaGenes UniPex colony macroarrays were screened using a
previously described procedure [12]. Version 4.0 of the Invitrogen
Protoarray was used for protein microarray screening experiments.
After blocking the array in blocking buffer (PBS, 1% BSA, 0.1%
Tween 20) for 1 h at 4uC, 10 mg aliquots of biotinylated NEMO or
GST control diluted in 120 ml of probing buffer (PBS containing
0.5 mM DTT, 5 mM MgCl2, 5% glycerol, 0.05% Triton X-100
and Calbiochem protease inhibitor cocktail) were added to the array
and the array covered and incubated at 4uC for a further 1.5 h.
Arrays were then washed three times in ice cold probing buffer prior
to the addition of streptavidin-alkaline phosphatase (Invitrogen)
diluted in probing buffer to a final concentration of 0.25 mg/ml.
Arrays were incubated for 30 min on ice, washed three times in
probing buffer and then dried for 2–3 h.
Arrays were imaged using a Perkin Elmer Scanarray Ex-
pressHT system and the images analyzed using Invitrogen
Prospector version 4 software. Significant interactions were
identified based on a Z-score cutoff value of 3.0, with the data
obtained from the biotin-GST experiment being subtracted from
those of the biotin-NEMO experiment.
GST Pulldown and Coimmunoprecipitation
GST pulldowns using purified GST-NEMO and transfected
HEK-293T cells expressing IKKb [47], CALB1 (Origene),
CDK2-HA [48], SAG (Origene), SENP2-FLAG [49] or SYT1-
FLAG (this study) were performed as described previously [12].
For coimmunoprecipitation, HEK293 cells were grown in 6-well
plates containing DMEM supplemented with 10% FBS to a
confluence of approximately 80%. After rinsing in serum-free
DMEM, cells were transfected with 4 mg of pcDNA4/HisMaxA-
NEMO [12] and each of the abovementioned plasmids using
Lipofectamine 2000 (Invitrogen). At 24 h post-transfection, cells
were gently rinsed in ice-cold PBS and scraped into 0.5 ml of lysis
buffer (20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 0.5% NP-40,
0.5 mM DTT, 10% glycerol, 2 mM EDTA, Calbiochem protease
inhibitor cocktail). The lysate was incubated with end-over-end
mixing for 30 min at 4uC and insoluble material pelleted by
centrifugation at 10,0006g for 20 min. Supernatants were
collected and used for coimmunoprecipitation. A 1 mg aliquot of
mouse monoclonal anti-Xpress (Invitrogen) was added to 400 ml
(500–750 mg total protein) of the cell lysates and the mixtures
incubated with end-over-end mixing for 2 h at 4uC. The resulting
immunocomplexes were precipitated by adding 25 ml bed volume
of protein A/G agarose (Santa Cruz Biotech) and further
incubating with mixing at 4uC for 2 h. The agarose beads were
then pelleted at 1,0006g for 3 min and washed three to five times
in chilled lysis buffer. Pellets were finally resuspended in 60 ml of
26Laemmli sample buffer, boiled, and the supernatants collected.
Aliquots of 20 ml were used for SDS-PAGE followed by anti-
FLAG, anti-Myc, anti-HA or anti-Xpress (Invitrogen) immuno-
blotting and detection with Dura chemiluminescent substrate
(Peirce).
Mammalian Two-Hybrid Assays
Protein-protein interactions were confirmed by two-hybrid
analysis using the CheckMate/Flexi system (Promega) with
HEK-293T cells. Two-hybrid complementation plasmids were
generated by Pfu polymerase-mediated PCR using the above-
mentioned plasmids as templates with cloning being performed
using SgfI and PmeI restriction digestion of pFN10A (activation
domain) and pFN11A (binding domain). Plasmid sequences were
validated by DNA sequencing. Firefly and Renilla luciferase
activities were determined using a Dual-Luciferase kit (Promega)
and expressed as normalized firefly/Renilla luciferase values.
NF-kB Reporter Ggene Assays
Transcriptional activation by NF-kB was monitored using a
secreted alkaline phosphatase (SEAP) reporter plasmid, pNF-kB-
SEAP, which contains four kB consensus sequences upstream of
SEAP [50]. HEK-293T cells were seeded in 24-well plates and
grown overnight in antibiotic-free DMEM containing 10% FCS to
approximately 60% confluence. Cells were then transfected with
400 ng of reporter plasmid and 1600 ng of the different expression
plasmids using Lipofectamine 2000 (Invitrogen) and serum-free
DMEM as recommended by the manufacturer. Medium was
replaced with serum-containing medium at 4–6 h post-transfec-
tion. At this point, cells were treated with TNFa (100 ng/ml) or
left untreated for a further 20 h. Culture supernatants were then
collected and heat-treated at 65uC for 5 min to inactivate
endogenous alkaline phosphatase. Cells were washed in PBS and
lysed directly using 50 ml of Laemmli sample buffer for protein
expression analysis by immunoblotting. SEAP was measured in
96-well plates by combining 10 ml of supernatant with 190 ml of
Attophos substrate (Roche) and incubating plates at room
temperature for 12 h prior to reading fluorescence with a BioTek
Synergy HT plate reader (Ex485/Em528).
RNA Interference
HEK-293T cells were transfected with 400 ng of the NF-kB
reporter plasmid as described above, along with 20 pmol of
siRNAs directed against CDK2 (Ambion Silencer siRNA S204),
SAG (Ambion Silencer siRNA S18473), SENP2 (Ambion Silencer
siRNA S34009) or a nonspecific control (Ambion Silencer control
siRNA). Pre-incubation of the siRNA and plasmid DNA with the
Lipofectamine 2000 was reduced to 5 min to reduce siRNA
degradation. Cells were incubated with the Lipofectamine 2000
complexes for 5 hours prior to replacement of the medium with
DMEM containing 10% FBS and further incubated for 48 h. The
medium was then replaced and the cells treated with TNFa for a
further 24 h, at which time the SEAP reporter activity was
determined as described above and cellular RNA prepared using a
Qiagen RNeasy kit and Invitrogen RNase-free DNase.
Quantitative PCR
Amounts of CDK2, SAG, SENP2 and 18s rRNA were
quantitated by RT-qPCR using a LightCycler RNA Master
SYBR Green I kit (Roche) with gene-specific primers CDK2-
FWD1 (59-GGAGAACTTCCAAAAGGTGG-39) and CDK2-
REV1 (59-TCTCGGATGGCAGTACTGGG-39), SAG-FWD1
(59-CGACGTGGAAGACGGAGAGGAA-39) and SAG-REV1
(59-TGCAGATGGCGCACGTATCG-39), SENP2 FWD1 (59-
ATGTACAGATGGCTGGTTAG-39) and SENP2 REV1 (59-
TGGTCTTTTGGCTGGTATTT-39), or 18S FWD1 (59-
GTAACCCGTTGAACCCCATT-39) and 18S REV1 (59-
CCATCCAATCGGTAGTAGCG-39). Amounts of each mRNA
were calculated relative to the 18S rRNA control and values
expressed as percentages of the control siRNA sample for each
siRNA knockdown.
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